FCH
UTHR icon

Freestone Capital Holdings’s United Therapeutics UTHR Stock Holding History

Freestone Capital Holdings’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,452
Closed -$873K – 366
2017
Q1 		$873K Sell
6,452
-2,294
-26% -$348K 0.07% 201
2016
Q4 		$1.25M Hold
8,746
– – 0.11% 166
2016
Q3 		$1.03M Sell
8,746
-2,973
-25% -$357K 0.09% 179
2016
Q2 		$1.24M Hold
11,719
– – 0.12% 151
2016
Q1 		$1.31M Buy
11,719
+3,059
+35% +$387K 0.14% 137
2015
Q4 		$1.36M Buy
+8,660
New +$1.26M 0.14% 114

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Freestone Capital Holdings's UTHR Position: Q2 2017 in Review

Freestone Capital Holdings sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 6,452 shares — an estimated $873K sold.

Freestone Capital Holdings first reported a position in UTHR in Q4 2015 and held it in 6 quarters. The position peaked at $1.36M in Q4 2015. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

  • Freestone Capital Holdings reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Freestone Capital Holdings sold 6,452 United Therapeutics shares in Q2 2017, an estimated $873K.
  • Freestone Capital Holdings first reported a position in United Therapeutics in Q4 2015 and held it in 6 quarters.
  • Freestone Capital Holdings's United Therapeutics position peaked at $1.36M in Q4 2015.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Freestone Capital Holdings's 13F filing for Q2 2017, filed 10 Aug 2017.